Update on clinical trials of antiplatelet therapy for cerebrovascular diseases

Cerebrovascular Diseases

Volumn 10, Issue SUPPL. 5, 2000, Pages 34-40

  Bhatt, Deepak L ^a   Kapadia, Samir R ^a   Yadav, Jay S ^a   Topol, Eric J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Aspirin; Clopidogrel; Dipyridamole; Glycoprotein IIb IIIa inhibitors; Platelets; Stroke; Ticlopidine

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DIPYRIDAMOLE; FIBRINOGEN RECEPTOR ANTAGONIST; TICLOPIDINE;

ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; FIBRINOLYTIC THERAPY; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SECONDARY PREVENTION; STROKE;

EID: 0033679411     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000047602     Document Type: Article

References (50)

1. Antiplatelet and anticoagulant therapy in the secondary prevention of ischemic heart disease
2. Recognition of the importance of embolization in atherosclerotic vascular disease
3. Embolization as a pathological mechanism
4. The symptomatic carotid plaque
5. Reduced microvascular thrombosis and improved outcome in acute murine stroke by inhibiting GP IIb/IIIa receptor-mediated platelet aggregation
6. Thromboembolic events predispose the brain to widespread cerebral infarction after delayed transient global ischemia in rats
7. Neuronal protection in stroke by an sLex-glycosylated complement inhibitory protein
8. Infarct volume, neurological severity and PAF binding to platelets of patients with acute cerebral ischemic stroke
9. Increased expression of P-selectin on platelets is a risk factor for silent cerebral infarction in patients with atrial fibrillation: Role of nitric oxide
10. Microemboli detected by transcranial Doppler monitoring in patients during carotid angioplasty versus carotid endarterectomy
11. Antiplatelet Trialists' Collaboration: Collaborative overview of randomised trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
12. Aspirin Trial: Interim results
13. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: A randomized controlled trial. ASA and Carotid Endarterectomy (ACE) Trial Collaborators
14. Final report on the aspirin component of the ongoing Physicians' Health Study
15. Aspirin and risk of hemorrhagic stroke: A meta-analysis of randomized controlled trials
16. Aspirin for the primary prevention of stroke and other major vascular events: Meta-analysis and hypotheses
17. Cardioembolic vs. noncardioembolic strokes in atrial fibrillation: Frequency and effect of antithrombotic agents in the stroke prevention in atrial fibrillation studies
18. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: A meta-analysis
19. CAST: Randomized placebo-controlled trial of early aspirin use in 20,000 patients with acute ischemic stroke
20. The International Stroke Trial (IST): A randomized trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischemic stroke
21. What have we learned from recent antiplatelet trials?
22. Antiplatelet therapy in acute cerebral ischemia
23. Development of aspirin resistance in persons with previous ischemic stroke
24. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke
25. Low-dose and high-dose acetylsalicylic acid, with and without dipyridamole: A review of clinical trial results
26. Rapid development of tolerance to dipyridamole-associated headaches
27. Dipyridamole plus aspirin in cerebrovascular disease
28. Benefit of clopidogrel in patients with coronary disease
29. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients
30. Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting
31. The recruitment triangle: Reasons why African Americans enroll, refuse to enroll, or voluntarily withdraw from a clinical trial: An interim report from the African-American Antiplatelet Stroke Prevention Study (AAASPS)
32. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
33. Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin
34. Choice of endpoints in antiplatelet trials: Which outcomes are most relevant to stroke patients?
35. Superiority of clopidogrel versus aspirin in patients with a history of diabetes mellitus
36. Complementary, additive benefit of clopidogrel and lipid-lowering therapy in patients with atherosclerosis
37. Marked superiority of clopidogrel versus aspirin in patients with a history of previous cardiac surgery
38. One year after CAPRIE, IST and ESPS 2: Any changes in concepts?
39. Combination of aspirin-clopidogrel therapy in patients with ischemic stroke
40. Clopidogrel use in carotid artery stenting
41. Clopidogrel may enhance the clinical efficacy of carotid artery stent implantation: The EMILY Registry
42. Causes and severity of ischemic stroke in patients with internal carotid artery stenosis
43. Abciximab in acute ischemic stroke: A randomized, double-blind, placebo-controlled, dose-escalation study
44. 2nd: Basilar artery rethrombosis: Successful treatment with platelet glycoprotein IIb/IIIa receptor inhibitor
45. Chimeric 7E3 prevents carotid artery thrombosis in cynomolgus monkeys
46. The evaluation of antiplatelet therapy for postoperative thromboembolism in carotid endarterectomy
47. Initial experience of glycoprotein IIb/IIIa inhibition with abciximab during carotid stenting: A safe adjunctive therapy
48. The platelet IIb/IIIa inhibitor abciximab as adjunctive therapy in carotid stenting of potential thrombotic lesions
49. Increased mortality with oral glycoprotein IIb/IIIa antagonists: A pooled analysis of the large scale oral glycoprotein IIb/IIIa trials